This announcement is a separate document:
GlaxoSmithKline | 6-K: Viiv Healthcare Presents Phase I Clinical Trial Findings of a Cabotegravir Long-Acting Injectable Investigational Formulation Allowing at Least Four Months Between Doses
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.